Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster
It is urgently needed to evaluate the necessity and benefits of booster vaccination against the coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2) Omicron to facilitate clinical decision-making for 2019 coronavirus disease (COVID-19) convalescents. We conducted a multicenter, prospective clinical trial (registration number: ChiCTR2100045810) in the first patients with COVID-19 from 28 January 2020 to 20 February 2020 to assess the long-term durability of neutralizing antibodies against live Omicron BA.5 and further assess the efficiency and safety of CoronaVac in the convalescent group. A total of 96 COVID-19 convalescents were enrolled in this study. Neutralizing antibody titers in convalescents were significantly reduced in 9-10 months. A dose-refreshing vaccination in 28 convalescents with an antibody titer below 96 significantly induced neutralizing antibodies against live Omicron by 4.84-fold. Meanwhile, the abundance of naive T cells increased dramatically, and TEMRA and TEM cells gradually decreased after vaccination. Activation-induced cell death and apoptosis-related genes were significantly elevated after vaccination in all T-cell subtypes. One-dose booster vaccination was effective in inducing a robust antibody response against SARS-CoV-2 Omicron in COVID-19 convalescents with low antibody titers. However, vaccine-mediated T-cell consumption and regeneration patterns may be detrimental to the antiviral response.IMPORTANCEThe globally dominant coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2) Omicron variant raises the possibility of repeat infections among 2019 coronavirus disease (COVID-19) convalescents with low neutralizing antibody titers. The importance of this multicenter study lies in its evaluation of the long-term durability of neutralizing antibodies in COVID-19 convalescents and the efficacy of a booster vaccination against the live Omicron. The findings suggest that a one-dose booster vaccination is effective in inducing a robust antibody response against SARS-CoV-2 Omicron in convalescents with low antibody titers. However, the study also highlights the potential detrimental effects on the antiviral response due to vaccine-mediated T-cell consumption and regeneration patterns. These results are crucial for facilitating clinical decision-making for COVID-19 convalescents and informing public health policies regarding booster vaccinations.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Microbiology spectrum - 12(2024), 3 vom: 05. März, Seite e0243523 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Zhao, Jingmin [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antibodies, Neutralizing |
---|
Anmerkungen: |
Date Completed 06.03.2024 Date Revised 13.03.2024 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1128/spectrum.02435-23 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM368083780 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM368083780 | ||
003 | DE-627 | ||
005 | 20240314235034.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240206s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1128/spectrum.02435-23 |2 doi | |
028 | 5 | 2 | |a pubmed24n1329.xml |
035 | |a (DE-627)NLM368083780 | ||
035 | |a (NLM)38319108 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Zhao, Jingmin |e verfasserin |4 aut | |
245 | 1 | 0 | |a Increased antibody titers but induced T cell AICD and apoptosis response in COVID-19 convalescents by inactivated vaccine booster |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 06.03.2024 | ||
500 | |a Date Revised 13.03.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a It is urgently needed to evaluate the necessity and benefits of booster vaccination against the coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2) Omicron to facilitate clinical decision-making for 2019 coronavirus disease (COVID-19) convalescents. We conducted a multicenter, prospective clinical trial (registration number: ChiCTR2100045810) in the first patients with COVID-19 from 28 January 2020 to 20 February 2020 to assess the long-term durability of neutralizing antibodies against live Omicron BA.5 and further assess the efficiency and safety of CoronaVac in the convalescent group. A total of 96 COVID-19 convalescents were enrolled in this study. Neutralizing antibody titers in convalescents were significantly reduced in 9-10 months. A dose-refreshing vaccination in 28 convalescents with an antibody titer below 96 significantly induced neutralizing antibodies against live Omicron by 4.84-fold. Meanwhile, the abundance of naive T cells increased dramatically, and TEMRA and TEM cells gradually decreased after vaccination. Activation-induced cell death and apoptosis-related genes were significantly elevated after vaccination in all T-cell subtypes. One-dose booster vaccination was effective in inducing a robust antibody response against SARS-CoV-2 Omicron in COVID-19 convalescents with low antibody titers. However, vaccine-mediated T-cell consumption and regeneration patterns may be detrimental to the antiviral response.IMPORTANCEThe globally dominant coronavirus 2 of the severe acute respiratory syndrome (SARS-CoV-2) Omicron variant raises the possibility of repeat infections among 2019 coronavirus disease (COVID-19) convalescents with low neutralizing antibody titers. The importance of this multicenter study lies in its evaluation of the long-term durability of neutralizing antibodies in COVID-19 convalescents and the efficacy of a booster vaccination against the live Omicron. The findings suggest that a one-dose booster vaccination is effective in inducing a robust antibody response against SARS-CoV-2 Omicron in convalescents with low antibody titers. However, the study also highlights the potential detrimental effects on the antiviral response due to vaccine-mediated T-cell consumption and regeneration patterns. These results are crucial for facilitating clinical decision-making for COVID-19 convalescents and informing public health policies regarding booster vaccinations | ||
650 | 4 | |a Clinical Trial | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Multicenter Study | |
650 | 4 | |a Omicron | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a T cells | |
650 | 4 | |a cell death | |
650 | 4 | |a convalescents | |
650 | 4 | |a vaccine | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
650 | 7 | |a Antibodies, Viral |2 NLM | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Vaccines, Inactivated |2 NLM | |
700 | 1 | |a Zhang, Han |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Lina |e verfasserin |4 aut | |
700 | 1 | |a Cheng, Fang |e verfasserin |4 aut | |
700 | 1 | |a Li, Wei |e verfasserin |4 aut | |
700 | 1 | |a Wang, Zihao |e verfasserin |4 aut | |
700 | 1 | |a Liu, Hongyang |e verfasserin |4 aut | |
700 | 1 | |a Li, Shaohua |e verfasserin |4 aut | |
700 | 1 | |a Jiang, Yiyun |e verfasserin |4 aut | |
700 | 1 | |a Li, Meiling |e verfasserin |4 aut | |
700 | 1 | |a Li, Yan |e verfasserin |4 aut | |
700 | 1 | |a Liu, Shuhong |e verfasserin |4 aut | |
700 | 1 | |a Fang, Min |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Xuyu |e verfasserin |4 aut | |
700 | 1 | |a Ye, Xin |e verfasserin |4 aut | |
700 | 1 | |a Zhao, Shousong |e verfasserin |4 aut | |
700 | 1 | |a Zheng, Yuxuan |e verfasserin |4 aut | |
700 | 1 | |a Meng, Songdong |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Microbiology spectrum |d 2013 |g 12(2024), 3 vom: 05. März, Seite e0243523 |w (DE-627)NLM241847044 |x 2165-0497 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2024 |g number:3 |g day:05 |g month:03 |g pages:e0243523 |
856 | 4 | 0 | |u http://dx.doi.org/10.1128/spectrum.02435-23 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2024 |e 3 |b 05 |c 03 |h e0243523 |